Finerenone Just Got Priority Review for Type 1 Diabetes and This Drug Signals Exactly Where the Pharmacist’s Future Lies
On May 21, 2026, Bayer announced that the FDA granted Priority Review to a supplemental NDA for finerenone (Kerendia) in a new indication that…